NASDAQ: SNTI
Senti Biosciences Holdings Inc Stock Forecast, Predictions & Price Target

Analyst price target for SNTI

Based on 1 analyst offering 12 month price targets for Senti Biosciences Holdings Inc

Min Forecast
$12.00+1,150%
Avg Forecast
$12.00+1,150%
Max Forecast
$12.00+1,150%

Should I buy or sell SNTI stock?

Based on 1 analyst offering ratings for Senti Biosciences Holdings Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SNTI stock forecasts and price targets.

SNTI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-15

1 of 1

Forecast return on equity

Is SNTI forecast to generate an efficient return?

Company
-1,176.58%
Industry
95.51%
Market
175.55%
SNTI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SNTI forecast to generate an efficient return on assets?

Company
-78.92%
Industry
28.06%
SNTI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SNTI earnings per share forecast

What is SNTI's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.21
Avg 2 year Forecast
-$0.97
Avg 3 year Forecast
-$1.37

SNTI revenue forecast

What is SNTI's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$34.0k-10.53%
Avg 2 year Forecast
$51.0k+34.21%
Avg 3 year Forecast
$10.5M+27,547.37%
SNTI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SNTI revenue growth forecast

How is SNTI forecast to perform vs Biotechnology companies and vs the US market?

Company
510.91%
Industry
33.61%
Market
13.79%
SNTI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SNTI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SNTI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SNTI$0.96$12.00+1,150.00%Strong Buy
DARE$2.02N/AN/A
RADX$4.27$16.00+274.71%Strong Buy
EVAX$3.64$12.50+243.41%Strong Buy
QCLS$3.87N/AN/A

Senti Biosciences Holdings Stock Forecast FAQ

Is Senti Biosciences Holdings Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SNTI) stock is to Strong Buy SNTI stock.

Out of 1 analyst, 1 (100%) are recommending SNTI as a Strong Buy, 0 (0%) are recommending SNTI as a Buy, 0 (0%) are recommending SNTI as a Hold, 0 (0%) are recommending SNTI as a Sell, and 0 (0%) are recommending SNTI as a Strong Sell.

If you're new to stock investing, here's how to buy Senti Biosciences Holdings stock.

What is SNTI's earnings growth forecast for 2026-2028?

(NASDAQ: SNTI) Senti Biosciences Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.

Senti Biosciences Holdings's earnings in 2026 is -$51,547,000.On average, 6 Wall Street analysts forecast SNTI's earnings for 2026 to be -$37,591,718, with the lowest SNTI earnings forecast at -$39,983,635, and the highest SNTI earnings forecast at -$33,356,032. On average, 4 Wall Street analysts forecast SNTI's earnings for 2027 to be -$30,179,267, with the lowest SNTI earnings forecast at -$29,300,985, and the highest SNTI earnings forecast at -$30,739,872.

In 2028, SNTI is forecast to generate -$42,727,488 in earnings, with the lowest earnings forecast at -$60,128,062 and the highest earnings forecast at -$23,545,434.

What is SNTI's revenue growth forecast for 2026-2028?

(NASDAQ: SNTI) Senti Biosciences Holdings's forecast annual revenue growth rate of 510.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.

Senti Biosciences Holdings's revenue in 2026 is $38,000.On average, 6 Wall Street analysts forecast SNTI's revenue for 2026 to be $1,058,828, with the lowest SNTI revenue forecast at $0, and the highest SNTI revenue forecast at $3,270,199. On average, 4 Wall Street analysts forecast SNTI's revenue for 2027 to be $1,588,382, with the lowest SNTI revenue forecast at $0, and the highest SNTI revenue forecast at $3,270,199.

In 2028, SNTI is forecast to generate $327,206,786 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $673,661,029.

What is SNTI's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SNTI) forecast ROA is -78.92%, which is lower than the forecast US Biotechnology industry average of 28.06%.

What is SNTI's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SNTI price target, the average SNTI price target is $12.00, with the highest SNTI stock price forecast at $12.00 and the lowest SNTI stock price forecast at $12.00.

The Wall Street analyst predicted that Senti Biosciences Holdings's share price could reach $12.00 by May 15, 2027. The average Senti Biosciences Holdings stock price prediction forecasts a potential upside of 1,150% from the current SNTI share price of $0.96.

What is SNTI's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SNTI) Senti Biosciences Holdings's current Earnings Per Share (EPS) is -$1.87. On average, analysts forecast that SNTI's EPS will be -$1.21 for 2026, with the lowest EPS forecast at -$1.28, and the highest EPS forecast at -$1.07. On average, analysts forecast that SNTI's EPS will be -$0.97 for 2027, with the lowest EPS forecast at -$0.94, and the highest EPS forecast at -$0.99. In 2028, SNTI's EPS is forecast to hit -$1.37 (min: -$1.93, max: -$0.76).

What is SNTI's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SNTI) forecast ROE is -1,176.58%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.